111In-DTPA0-octreotide (Octreoscan), 131I-MIBG and other agents for radionuclide therapy of NETs

摘要: This paper is a critical review of the literature on NET radionuclide therapy with 111In-DTPA0-octreotide (Octreoscan) and 131I-MIBG, focusing efficacy toxicity. Some potential future applications new candidate therapeutic agents are also mentioned. Octreoscan has been pioneering agent for somatostatin receptor therapy. It achieved symptomatic responses disease stabilization, but it now outperformed by corresponding β-emitter 177Lu-DOTATATE 90Y-DOTATOC. 131I-MIBG choice inoperable or metastatic phaeochromocytomas/paragangliomas, which avidly concentrate this tracer via noradrenaline transporter. Symptomatic, biochemical tumour morphological response rates 50–89%, 45–74% 27–47%, respectively, have reported. second-line radiopharmaceutical treatment enterochromaffin carcinoids, mainly offering benefit amelioration hormone-induced symptoms. High specific activity, non-carrier-added meta-astato(211At)-benzylguanidine (MABG) tracers enhanced efficacy, yet their integration into clinical practice awaits further exploration. Amongst other promising agents, radiolabelled exendin analogues show imaging possibly insulinomas, while preclinical studies currently evaluating DOTA peptides targeting CCK-2/gastrin receptors that overexpressed medullary thyroid carcinoma cells.